Protein clues may unlock better MG treatment monitoring
NCT ID NCT07337395
First seen Jan 15, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study will analyze blood proteins in 24 adults with generalized myasthenia gravis (MG) who are starting treatment with ravulizumab. The goal is to find protein changes that show how well the treatment is working and whether the nerve-muscle connection is healing. By identifying these biomarkers, doctors hope to personalize care and improve outcomes for people with MG.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS GENERALISED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.